Clinical Research Directory

Inclusion Criteria: Phase 0 (Proof-of-Concept) * Patients with one of the following: * Early-stage breast cancer having completed participation in IRB# 15-147 * Diagnosed with the prespecified solid tumors: endometrial, breast or prostate cancer * Underwent a diagnostic lung biopsy within 14 days prior to enrollment * Age \>18 years * BMI ≤ 40 * Has ≥ 20 mg of fresh normal lung and suspicious lung tissue from the standard of care diagnostic biopsy available for snap freezing and single-cell sequencing (lung patients only) * At least a 2-week window from study enrollment to scheduled surgical resection (patients with prespecified solid tumors only) * Performing less than 30 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluation by self report If \> 30 minutes but less than 90 minutes, patients may be eligible, at the discretion of the PI. * Cleared for exercise participation as per screening clearance via PAR-Q+ * Willingness to comply with all study-related procedures Phase 1a (Dose-Finding/Escalation) * Patients with operable untreated prostate cancer scheduled for surgery * At least a 2-week window from study enrollment to scheduled surgical resection (patients with prespecified solid tumors only) * Age \> 18 years * BMI \</=40 * If BMI \>40, patients may be eligible, at the discretion of the PI * Performing \</= 30 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluation by self report If \> 30 minutes but less than 90 minutes, patients may be eligible, at the discretion of the PI. * Cleared for exercise participation as per screening clearance via PAR-Q+ * Willingness to comply with all study-related procedures Exclusion Criteria: * Use of any selective estrogen receptor modulator or aromatase inhibitor within 6 months of study entry, including, but not limited to: tamoxifen, raloxifene, arzoxifene, acolbifene, anastrozole, exemestane, and letrozole (for preoperative breast, endometrial, and prostate patients in Phase 0 only) * Enrollment onto any other interventional investigational study except interventions determined by the PI not to confound the effect of exercise on study outcomes * Men receiving GNRH agonists and antagonists as well as any antiandrogrens * Any neoadjuvant anticancer treatment of any kind for the cancer of interest * Any history of systemic anticancer therapy * Any other diagnosis of invasive cancer currently requiring active treatment * Metastatic malignancy of any kind * Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation.